Contextual Considerations and Recommendations for Estimating the Value of Alzheimer's Disease Therapies
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG..
The pipeline for new treatments for Alzheimer's disease (AD) in the USA contains over 100 different agents, 80% of which can be categorized as disease-modifying therapies. The regulatory approval of the disease-modifying agent aducanumab has brought more attention to the complexity of the diagnosis, evaluation, and treatment of AD and the difficult decisions payers and policy makers will face over the next few years as innovation continues in this space. The value of AD treatment can vary widely according to the perspective of the analysis, sources of data, and methodological approach for the value assessment. This article focuses on AD-specific data gaps and measurement challenges and provides guidance for evidence generation to facilitate better value assessments for future AD treatments.
| Errataetall: |
ErratumIn: Pharmacoeconomics. 2022 Mar;40(3):355. - PMID 35075543 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
PharmacoEconomics - 39(2021), 10 vom: 23. Okt., Seite 1101-1107 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mattingly, T Joseph [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 27.10.2021 Date Revised 25.01.2022 published: Print-Electronic ErratumIn: Pharmacoeconomics. 2022 Mar;40(3):355. - PMID 35075543 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s40273-021-01079-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330961373 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330961373 | ||
| 003 | DE-627 | ||
| 005 | 20231225212424.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40273-021-01079-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1103.xml |
| 035 | |a (DE-627)NLM330961373 | ||
| 035 | |a (NLM)34554383 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mattingly, T Joseph |c 2nd |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Contextual Considerations and Recommendations for Estimating the Value of Alzheimer's Disease Therapies |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2021 | ||
| 500 | |a Date Revised 25.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Pharmacoeconomics. 2022 Mar;40(3):355. - PMID 35075543 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG. | ||
| 520 | |a The pipeline for new treatments for Alzheimer's disease (AD) in the USA contains over 100 different agents, 80% of which can be categorized as disease-modifying therapies. The regulatory approval of the disease-modifying agent aducanumab has brought more attention to the complexity of the diagnosis, evaluation, and treatment of AD and the difficult decisions payers and policy makers will face over the next few years as innovation continues in this space. The value of AD treatment can vary widely according to the perspective of the analysis, sources of data, and methodological approach for the value assessment. This article focuses on AD-specific data gaps and measurement challenges and provides guidance for evidence generation to facilitate better value assessments for future AD treatments | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a McQueen, R Brett |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Pei-Jung |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PharmacoEconomics |d 1992 |g 39(2021), 10 vom: 23. Okt., Seite 1101-1107 |w (DE-627)NLM09167039X |x 1179-2027 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2021 |g number:10 |g day:23 |g month:10 |g pages:1101-1107 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40273-021-01079-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2021 |e 10 |b 23 |c 10 |h 1101-1107 | ||